A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
复制标题
DOI：
10.1128/jvi.00689-22
复制
发表时间：
2022-08-10
影响因子：
5.4
通讯作者：
中科院分区：
文献类型：
--
作者：
针对SARS-CoV-2的疫苗已被证明是非常有效的;然而，针对新出现的变体的广度和保护的寿命仍不清楚。免疫后加强已被证明对疾病保护有益，随着新变种的不断出现，可能会建议定期（也许每年）接种疫苗。由于持续的抗原漂移，目前每年都需要开发新的季节性流感病毒疫苗，这一任务是由强大的全球疫苗生产和分销基础设施完成的。为了创造一种同时靶向流感病毒和SARS-CoV-2的季节性联合疫苗，该疫苗也适合频繁的重新配制，我们开发了一种甲型流感病毒（IAV）遗传平台，该平台允许将SARS-CoV-2刺突蛋白的免疫原性结构域掺入IAV颗粒上。用该组合疫苗接种引起中和抗体，并在小鼠中提供对两种病原体的致死性攻击的保护。这种方法可以允许利用已建立的流感疫苗基础设施来产生针对流感和冠状病毒的具有成本效益且可扩展的季节性疫苗解决方案。重要性自大流行开始以来，SARS-CoV-2变异株的迅速出现突出了对定期疫苗接种“加强”和可以快速重新配制以制造新疫苗的平台的需要。在这项工作中，我们报告了一种方法，可以利用目前的流感疫苗生产基础设施，以产生能够保护从流感病毒和SARS-CoV-2诱导的疾病的组合疫苗。流感/SARS-CoV-2联合疫苗的生产可能代表了一种实用的解决方案，可以提高对这些重要呼吸道病毒的免疫力，而不会增加多种独立疫苗的成本和管理负担。
Vaccines targeting SARS-CoV-2 have been shown to be highly effective; however, the breadth against emerging variants and the longevity of protection remains unclear. Postimmunization boosting has been shown to be beneficial for disease protection, and as new variants continue to emerge, periodic (and perhaps annual) vaccination will likely be recommended. New seasonal influenza virus vaccines currently need to be developed every year due to continual antigenic drift, an undertaking made possible by a robust global vaccine production and distribution infrastructure. To create a seasonal combination vaccine targeting both influenza viruses and SARS-CoV-2 that is also amenable to frequent reformulation, we have developed an influenza A virus (IAV) genetic platform that allows the incorporation of an immunogenic domain of the SARS-CoV-2 spike (S) protein onto IAV particles. Vaccination with this combination vaccine elicited neutralizing antibodies and provided protection from lethal challenge with both pathogens in mice. This approach may allow the leveraging of established influenza vaccine infrastructure to generate a cost-effective and scalable seasonal vaccine solution for both influenza and coronaviruses. IMPORTANCE The rapid emergence of SARS-CoV-2 variants since the onset of the pandemic has highlighted the need for both periodic vaccination “boosts” and a platform that can be rapidly reformulated to manufacture new vaccines. In this work, we report an approach that can utilize current influenza vaccine manufacturing infrastructure to generate combination vaccines capable of protecting from both influenza virus- and SARS-CoV-2-induced disease. The production of a combined influenza/SARS-CoV-2 vaccine may represent a practical solution to boost immunity to these important respiratory viruses without the increased cost and administration burden of multiple independent vaccines.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.6
作者：
Nogales A;Martínez-Sobrido L
通讯作者：
Martínez-Sobrido L
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
64.8
作者：
Mlcochova P;Kemp SA;Dhar MS;Papa G;Meng B;Ferreira IATM;Datir R;Collier DA;Albecka A;Singh S;Pandey R;Brown J;Zhou J;Goonawardane N;Mishra S;Whittaker C;Mellan T;Marwal R;Datta M;Sengupta S;Ponnusamy K;Radhakrishnan VS;Abdullahi A;Charles O;Chattopadhyay P;Devi P;Caputo D;Peacock T;Wattal C;Goel N;Satwik A;Vaishya R;Agarwal M;Indian SARS-CoV-2 Genomics Consortium (INSACOG);Genotype to Phenotype Japan (G2P-Japan) Consortium;CITIID-NIHR BioResource COVID-19 Collaboration;Mavousian A;Lee JH;Bassi J;Silacci-Fegni C;Saliba C;Pinto D;Irie T;Yoshida I;Hamilton WL;Sato K;Bhatt S;Flaxman S;James LC;Corti D;Piccoli L;Barclay WS;Rakshit P;Agrawal A;Gupta RK
通讯作者：
Gupta RK
DOI：
10.3390/v12090987
发表时间：
2020-09-05
期刊：
Viruses
影响因子：
--
作者：
Loes AN;Gentles LE;Greaney AJ;Crawford KHD;Bloom JD
通讯作者：
Bloom JD